Recently published Complement Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, ...

SEOUL, South Korea, June 02, 2025--(BUSINESS WIRE)--ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...

Although many things can affect your individual prognosis, about half of all patients will reach kidney failure within 10 years of their diagnosis and need dialysis or a kidney transplant. Even after ...

Omeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...